# Safety and Efficacy of Xalkori ROS1

> **NCT03375242** · — · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 97 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** crizotinib

## Key facts

- **NCT ID:** NCT03375242
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-25
- **Primary completion:** 2026-11-06
- **Final completion:** 2026-11-06
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03375242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03375242, "Safety and Efficacy of Xalkori ROS1". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03375242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*